Revenue

Ghost Robotics' new arm gives its Vision 60 the power to act. This leap from seeing to doing has huge implications for industries from defense to healthcare.

With a new $6.5M investment, Double is tackling the accounting talent crisis with AI that empowers professionals, not replaces them. Here's why.

As lithium fire risks escalate, a small-cap firm's live EV burn demo in Houston draws industry giants, signaling a pivotal moment for safety tech.

As esports races toward a $7.5B market, specialized hardware is king. Inside ZOWIE's strategy to win the high-stakes game of competitive tech.

How TerraVest's aggressive acquisition spree is reshaping industrial markets and delivering substantial returns to shareholders. Dive into the strategy.

A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.

Nasdaq-listed Caliber moves beyond passive holding, staking 75,000 LINK to actively generate yield. A look at the high-stakes strategy bridging Wall Street and Web3.

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

Lindsay Corp.'s massive irrigation project in MENA isn't just a sale; it's a strategic move in the high-stakes race to solve global food security.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

Sarepta Therapeutics is trading higher interest costs for a longer financial runway. We decode the biotech's complex debt deal and what it signals.

The U.S. Coast Guard taps AeroVironment for advanced underwater robots, a key step in its Force Design 2028 plan to boost safety and mission efficiency.

As agencies retool for a complex market, Bastion's appointment of a cultural PR expert highlights a critical shift for pharma and beyond.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Canadian grocer Empire posts strong sales but lower earnings. A deep dive into its dual strategy of store renewal and a major digital and data overhaul.